Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,250.00
Ask: 12,700.00
Change: 0.00 (0.00%)
Spread: 450.00 (3.673%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,556.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Value picks for a rising dollar world

Thu, 08th Apr 2021 12:15

* European shares hit new record high

* STOXX 600 up 0.3%, FTSE 100 up 0.4%

* FOMC minutes send dovish message

* Nasdaq leads U.S. futures higher

April 8 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

VALUE PICKS FOR A RISING DOLLAR WORLD (1112 GMT)

With the rotation into value plays still underway and the
U.S. dollar on a recovery path from near one-year lows,
stockpickers way well be looking for companies that are
positively exposed to both trends.

Citi, who expects the dollar to rise further this year, has
done the job by screening out some cheap and un-crowded U.S. and
European names that have a significant positive exposure to the
greenback.

"Value has become more positively exposed to a stronger US
dollar making it the new tailwind, while the impact of interest
rates has begun to wane," they say, adding that "a strong US$ is
a headwind for Growth and Price Momentum".

Some names?

Sorted by their dollar exposure the top three buy-rated
value stocks that aren't very crowded are Syneos Health
, Aroundtown and Novartis.

Down in the list to reach position No.10 are Continental
and British American Tobacco, DISH Network
, Ahold, Deutsche Wohnen and Vodafone
and Leg Immobilien.

The influence of the dollar has increased significantly.

As you see in this Citi chart, the return correlation has
steadily risen in March to reach the highest level this year.

(Danilo Masoni)

*****

INSURERS: TAKE A LOOK AT SOLVENCY RATIOS (1033 GMT)

With shares of European insurers trading at a significant
discount to the benchmark Stoxx 600 index, the picture is
getting attractive amid rising solvency ratio estimates.

UBS says estimates for solvency ratio -- a company's ability
to meet its long-term obligations -- for the sector "increased
by +8 ppts on average since FY20 to 199% driven largely by the
increase in interest rates."

This "screens well both for downside protection but also for
potential for upside to dividend/capital return," according to
them.

With the sector trading at a 40% discount to the Eurostoxx,
compared to its historical average of 20%, this higher solvency,
along with macro tailwinds, "means the sector's capital return
screens attractive," they say.

Among single names, UBS says Generali (231%), NN Group
(216%) and Aviva (209%) standout with the highest solvency
ratios.

Chart below shows European insurer stocks
underperforming the Stoxx 600.

(Stefano Rebaudo)

*****

NEW RECORD HIGH FOR STOXX (0847 GMT)

European shares are off to a positive start this morning
with the STOXX 600 making a fresh record high in early deals and
the FTSE 100 hitting its highest in more than a year, helped by
dovish messaging from the Fed minutes.

The pan European benchmark was last up 0.3% while the UK's
top share index added 0.1%, both off initial highs.

"Investors’ risk appetite is on the rise again as the Fed
officials renewed their dovish tone yesterday by announcing that
the massive bond-buying program will continue for 'some time',”
said Pierre Veyret, analyst at ActivTrades.

"The mood has been further strengthened by Janet Yellen
confirming a $2 trillion fiscal aid plan in the US," he added.

In single stocks worth highlighting that telco M&A is back.

KPN shares are rising 2.3% after a media report said private
investors were preparing an attempt to buy the top Dutch
telecoms provider. KPN declined to comment.

(Danilo Masoni)

*****

KEEP THE FAIT (0709 GMT)

The messages from the Fed's minutes could not be clearer.
First, despite the blowout March payrolls report, labour markets
are nowhere near its threshold for reining in easy monetary
policy. And the Fed aims to let inflation average 2% for some
time before contemplating any tightening.

In short: FAIT or flexible average inflation targeting.

The message seems to have sunk in - 10-year Treasury yields
are some 10 basis points off recent highs, a spike in
short-dated yields has abated and some of the most aggressive
pricing of Fed rate hikes has been scaled back.

Markets will await Fed Chair Jay Powell's appearance at the
IMF spring meetings but the minutes have lifted U.S. equity
futures half a percent, following Wednesday's records on Wall
Street. European stocks are opening higher too, with the UK's
FTSE looking to extend its Wednesday run to record highs.

On the economy front, strong German domestic demand lifted
industrial orders for the second straight month, hot on the
heels of this week's PMI revisions that showed euro zone
business activity back in growth.

The fly -- (or the virus) -- in the ointment is of course
COVID-19 with infections surging in India, Tokyo set for
emergency measures and some evidence of blood clots linked to
the Astra Zeneca vaccine.

Key developments that should provide more direction to
markets on Thursday:

- Corporates: Holland-based Prosus sold 2% of
Chinese gaming giant Tencent for $14.7 billion in the
largest-ever block trade; Clothing retailers Asos and Uniqlo
reported robust profits, the former seeing an astonishing 275%
leap.

- Japan's consumer confidence improved in March.

- G20 finance officials to debate President Joe Biden's
minimum corporate tax plan

- Data: Euro zone, UK construction PMI; Euro zone PPI Feb;
U.S. weekly jobless numbers

- IMF/World Bank Spring Meetings: World Bank head Kristalina
Georgieva, Fed Chairman Powell, and WTO Director General Ngozi
Okonjo-Iweala to speak

- ECB: Vice President Luis de Guindos speaks

- Emerging markets: Peru, Sri Lanka central bank meetings

(Sujata Rao)

*****

EUROPEAN BOURSES SEEN ON THE BLACK AFTER FED MINUTES (0535
GMT)

In a data heavy morning, European shares are seen in the
black this morning after the Fed renewed its commitment to
keeping policy super loose even as the U.S. economy enjoys a
rapid recovery.

Fed remains wary about the ongoing risks of the pandemic and
is committed to bolstering the economy until its recovery is
more secure, according to minutes of the U.S. central bank’s
latest policy meeting.

U.S. stock futures just hit fresh record highs, while
European futures are also in positive territory.

Eyes will also be on PMI figures for the UK and the EZ,
which are due this morning.

Financial spreadbetters at IG expect London's FTSE to open
23 points higher at 6,909, Frankfurt's DAX to open 62 points
higher at 15,239 and Paris' CAC to open 27 points higher at
6,158.

(Joice Alves)

*****

More News
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.